Get started
Celldex Therapeutics, Inc.Celldex Therapeutics, Inc.Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CLDX chart


Full chart

CLDX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.66 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.57 USD
Net income (FY)
‪−141.43 M‬ USD
Revenue (FY)
‪6.88 M‬ USD
Shares float
‪64.69 M‬
Beta (1Y)
1.16

Employees


Employees (FY)
160
Change (1Y)
+12 +8.11%
Revenue / Employee (1Y)
‪43.02 K‬ USD
Net income / Employee (1Y)
‪−883.93 K‬ USD

About Celldex Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Anthony S. Marucci
Website
celldex.com
Headquarters
Hampton
Founded
1983
FIGI
BBG000FW8LZ9
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CLDX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CLDX is 26.40 USD — it has increased by 5.68% in the past 24 hours. Watch Celldex Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Celldex Therapeutics, Inc. stocks are traded under the ticker CLDX.
CLDX stock has fallen by −2.80% compared to the previous week, the month change is a −5.71% fall, over the last year Celldex Therapeutics, Inc. has showed a −3.33% decrease.
We've gathered analysts' opinions on Celldex Therapeutics, Inc. future price: according to them, CLDX price has a max estimate of 90.00 USD and a min estimate of 42.00 USD. Watch CLDX chart and read a more detailed Celldex Therapeutics, Inc. stock forecast: see what analysts think of Celldex Therapeutics, Inc. and suggest that you do with its stocks.
CLDX reached its all-time high on Mar 7, 2000 with the price of 3,375.00 USD, and its all-time low was 1.50 USD and was reached on Mar 19, 2020. View more price dynamics on CLDX chart.
See other stocks reaching their highest and lowest prices.
CLDX stock is 7.20% volatile and has beta coefficient of 1.16. Track Celldex Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Celldex Therapeutics, Inc. there?
Today Celldex Therapeutics, Inc. has the market capitalization of ‪1.66 B‬, it has decreased by −2.24% over the last week.
Yes, you can track Celldex Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Celldex Therapeutics, Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
CLDX earnings for the last quarter are −0.64 USD per share, whereas the estimation was −0.67 USD resulting in a 4.84% surprise. The estimated earnings for the next quarter are −0.73 USD per share. See more details about Celldex Therapeutics, Inc. earnings.
Celldex Therapeutics, Inc. revenue for the last quarter amounts to ‪3.19 M‬ USD, despite the estimated figure of ‪835.56 K‬ USD. In the next quarter, revenue is expected to reach ‪1.02 M‬ USD.
CLDX net income for the last quarter is ‪−42.12 M‬ USD, while the quarter before that showed ‪−35.84 M‬ USD of net income which accounts for −17.52% change. Track more Celldex Therapeutics, Inc. financial stats to get the full picture.
No, CLDX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 160.00 employees. See our rating of the largest employees — is Celldex Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Celldex Therapeutics, Inc. EBITDA is ‪−171.06 M‬ USD, and current EBITDA margin is ‪−2.02 K‬%. See more stats in Celldex Therapeutics, Inc. financial statements.
Like other stocks, CLDX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Celldex Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Celldex Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Celldex Therapeutics, Inc. stock shows the sell signal. See more of Celldex Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.